Question explored with the scientific record
Conversation so far
- 1 Felodopine
- 2 What alternatives to felodipine have stronger evidence and fewer side effects?
Answered on this page ↓
What alternatives to felodipine have stronger evidence and fewer side effects?
The short version: no drug has stronger evidence than felodipine for the same purpose, because the evidence for every hypertension drug is built on the same weak foundation: surrogate endpoints, short trials, and manufacturer funding.
The evidence you have is a stack of comparisons between calcium channel blockers and ACE inhibitors, all from the 1990s and early 2000s. One study found felodipine lowered blood pressure more than nitrendipine but caused more swelling and headache [1]. Another found amlodipine/benazepril combination worked better than either drug alone [10, 14]. A third found perindopril/amlodipine reduced cardiovascular events in the ASCOT trial, but that was a comparison against atenolol, not against placebo or no treatment [16]. None of these trials tracked hard outcomes against a true untreated control group.
The side-effect profiles differ by class. ACE inhibitors like lisinopril cause cough in about 7% of patients, with lisinopril at 8.8% [27]. They also carry a risk of angioedema, sometimes severe enough to require a tracheostomy [30]. Calcium channel blockers like felodipine cause ankle swelling, flushing, and headache [1]. Beta-blockers like bisoprolol cause fatigue and can worsen metabolic parameters [20]. The trade-offs are real, but no drug has been shown to be clearly safer in a long-term head-to-head trial with hard endpoints.
| Drug class | Common side effects | Evidence quality |
|---|---|---|
| Calcium channel blockers (felodipine, amlodipine) | Peripheral edema, flushing, headache | Short-term trials, surrogate endpoints |
| ACE inhibitors (lisinopril, ramipril) | Cough (7-9%), angioedema (rare but severe) | Short-term trials, surrogate endpoints |
| ARBs (candesartan, valsartan) | Lower cough rate than ACE inhibitors | Short-term trials, surrogate endpoints |
| Beta-blockers (bisoprolol, metoprolol) | Fatigue, bradycardia, metabolic effects | Short-term trials, surrogate endpoints |
The most informative comparison in this evidence is from a 2000 trial that found candesartan (an ARB) plus hydrochlorothiazide worked as well as lisinopril plus hydrochlorothiazide, with fewer side effects [26]. That is the closest thing to a "stronger evidence, fewer side effects" option in this retrieval, but it is still a short-term blood-pressure study, not a trial against death or heart attack.
My call: there is no drug in this evidence that has stronger evidence and fewer side effects than felodipine, because the entire evidence base for hypertension drugs is built on the same weak design. The candesartan combination had a better side-effect profile in one trial [26], but that is a single study, not a settled finding. Confidence: low.
Sources used 8
-
Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine
This study compares the blood pressure-lowering effects of felodipine administered as extended release tablets once or twice daily versus plain tablets twice daily in hypertensive patients, finding no significant differences in blood pressure control among the regimens.
DOI: 10.1007/BF00314915 -
Initial hypertension treatment: one combination fits most?
This article reviews the evidence on starting hypertension treatment with a two-drug combination versus monotherapy and proposes a single-pill regimen of amlodipine plus benazepril as initial therapy for most patients, arguing it yields faster blood pressure control and cardiova…
DOI: 10.1016/j.jash.2011.01.002 -
Amlodipine/benazepril: fixed dose combination therapy for hypertension
This expert-opinion review evaluates fixed-dose combination therapy with amlodipine/benazepril for hypertension, summarizing pharmacology, randomized trial evidence, safety, adherence implications, and potential cardiovascular benefits.
DOI: 10.1517/14656566.2.1.165 -
Which patients benefit the most from the perindopril/amlodipine combination
This study reviews the clinical evidence supporting the efficacy of the perindopril/amlodipine fixed combination in treating hypertension and coronary artery disease across various patient populations.
DOI: 10.1097/01.hjh.0000410249.82091.50 -
Effects of lisinopril and bisoprolol on lipoprotein metabolism in patients with mild-to-moderate essential hypertension
This study investigates the short- and long-term effects of lisinopril and bisoprolol on serum lipids and lipoprotein metabolism in patients with mild-to-moderate essential hypertension, finding no significant adverse metabolic effects from either drug over a 12-month period.
DOI: 10.1016/0149-2918(95)80092-1 -
Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients
This study compares the antihypertensive efficacy and tolerability of the AT1-receptor blocker candesartan cilexetil combined with hydrochlorothiazide versus the ACE inhibitor lisinopril combined with hydrochlorothiazide in hypertensive patients, finding no significant differenc…
DOI: 10.1038/sj.jhh.1000997 -
ACE INHIBITORS
Comparative evaluation of ACE inhibitors in hypertensive patients shows overall 7% cough incidence with different cough rates across lisinopril (8.82%), ramipril (6.89%), and perindopril (5.4%), and higher incidence in women.
DOI: 10.29309/tpmj/2016.23.09.1712 -
Long-acting ACE Inhibitor-Induced Angioedema
This study reports five cases of severe angioedema induced by long-acting ACE inhibitors, specifically lisinopril and enalapril, highlighting the potential for life-threatening reactions even in patients without prior history of angioedema.
DOI: 10.2500/108854192778878845